MTOR and melanoma: Literature data (Kim et al. 2017) and our own results (Ciołczyk-Wierzbicka and Laidler 2018; Ciołczyk-Wierzbicka et al. 2018) suggest that mTOR inhibitors – both rapamycin and everolimus – have significant impact on cell cycle regulation, reduction of cell proliferation and invasiveness of melanoma cells (Ciołczyk-Wierzbicka and Laidler 2018; Ciołczyk-Wierzbicka et al. 2018).